



NDA 21879/S-0012

SUPPLEMENT APPROVAL

Avanir Pharmaceuticals, Inc.
Attention: Mr. Gus Aromin
Senior Director, Regulatory Affairs
30 Enterprise, Suite 400
Aliso Viejo, CA 92656

Dear Mr. Aromin:

Please refer to your Supplemental New Drug Application (sNDA) dated August 3, 2018, received August 3, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) capsules, 20 mg/10 mg.

This Prior Approval supplemental new drug application provides for revisions to Section 8.5 (Use in Specific Populations; Geriatric Use) of the prescribing information to convey information regarding use in geriatric patients and to be consistent with the requirements under 21 CFR 201.57(c)(9)(v)(B)(1) for drugs in which clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects, per our June 19, 2018, request.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling for the Prescribing Information, with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Michelle Mathers, Regulatory Project Manager, at michelle.mathers@fda.hhs.gov or at (240) 402- 2645.

Sincerely,

{See appended electronic signature page}

Alice Hughes, MD
Deputy Director for Safety
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:

Content of Labeling
Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ALICE HUGHES
01/31/2019 04:04:58 PM